COMP <GO>
PTCT vs COGT // FREE CASH FLOW YIELD
PTC Therapeutics Inc. (NASDAQ) VS. Cogent Biosciences Inc. (NASDAQ) • 15-METRIC TALLY: PTCT 8
— COGT 3
▲ FREE CASH FLOW YIELD LEADER: PTCT
LAST: $60.88 (+1.52%) • MKT CAP: $5.01B
fcf-yield
13.05%
LAST: $29.73 (-4.16%) • MKT CAP: $5.38B
fcf-yield
-4.80%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PTCT VS. COGT)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PTCT | COGT | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 85.00% | -35.00% | +120.00 | PTCT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 6.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | 13.05% | -4.80% | +17.85 | PTCT | /fcf-yield <GO> |
| Operating Margin | 50.10% | -21.50% | +71.60 | PTCT | /operating-margins <GO> |
| Net Profit Margin | 39.50% | -21.20% | +60.70 | PTCT | /net-margins <GO> |
| Revenue Growth (YoY) | 114.50% | 22.00% | +92.50 | PTCT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 1.73 | 10.84 | -9.11 | COGT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 5/9 | +4.00 | PTCT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 47.2 | -4.00 | COGT | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.15 | 1.05 | +0.10 | PTCT | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.6x | 22.0x | -15.40 | PTCT | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.01B | $5.38B | -$372.6M | COGT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PTCT REV | COGT REV | PTCT GROSS % | COGT GROSS % | PTCT FCF | COGT FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.73B | $933.4M | — | — | $702.3M | -$266.0M |
| FY 2024 | $806.8M | $772.6M | — | — | -$114.2M | -$208.4M |
| FY 2023 | $937.8M | $582.8M | — | — | -$200.6M | -$153.6M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PTCT // BETA 1.15
COGT // BETA 1.05